{"version":"1.0","type":"link","title":"Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study.","author_name":"Park SH 외","author_url":"https://prs-insight.online/author/Park%20SH","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167337","thumbnail_width":1200,"thumbnail_height":630}